PRINCETON -
Sonnet performed two independent in vivo proof-of-concept (POC) studies to show the biodistribution of interleukin-FHAB molecules to the tumor microenvironment (TME), using labs with expertise in radiolabeling biologics and in vivo biodistribution analysis. The labs employed different radiolabeling methodologies (99mTc or 89Zr) for mIL-12 and mIL12-FHAB, either with or without a polyhistidine tag (His-Tag). The two studies were completed using the B16F10 mouse melanoma model for measuring the accumulation of radiolabeled product and tumor volume inhibition over various time points. The key findings from both studies indicated that mIL12-FHAB had significantly higher tumor accumulation, 2.5-4.7 times higher on average at the longer time points, and increased retention when compared to mIL-12. Accumulation was demonstrated in tumors compared to normal mice, and was transient in liver, kidney, and other organs, as expected. Importantly, radiolabeled mIL12-FHAB also demonstrated measurable accumulation in the draining lymph nodes. Overall, these findings have important implications for therapeutic applications of any mono- (ILx-FHAB) or bi-functional (ILx-FHAB-ILy) molecules demonstrating enhanced tumor targeting and accumulation, as well as the potential for improved efficacy that could lead to a variety of drug candidates.
'In addition to the previous multiple data sets that have highlighted the extended pharmacokinetic properties of the FHAB technology along with improved activity relative to wild-type IL-12, this is the first formal evidence of tumor targeting, which I believe supports our best-in-class cancer drug development platform', commented
Sonnet previously compared three constructs, the FHAB, an anti-TGF- scFv, and an anti-TGF-FHAB fusion protein, to evaluate the generic potential for in vivo accumulation and retention in tumors by FHAB-albumin complexes using a 4T1 tumor-bearing mouse model, which has tumors that over-express TGF-. Accumulation and retention profiles were characterized over a 24-hour period by Western blot analysis of tumor extracts taken at 30 minutes, then at 4-, 12-, and 24-hours after dosing of each construct. The comparative data showed that the FHAB domain exhibited superior accumulation and retention in the tumor at all time points. In contrast, the anti-TGF- molecule, which lacked the FHAB domain, exhibited a rapid decline in abundance at 4 hours and was not detectable at 12 or 24 hours, thus exhibiting poor accumulation and retention in the tumor. By comparison, fusion of the FHAB domain to anti-TGF-, which created the anti-TGF-FHAB fusion protein, restored the accumulation and retention profile in the tumor extracts tested at all time points, thus proving that the FHAB-albumin complex is driving anti-TGF- into the tumor, while the anti-TGF- molecule without FHAB did not. In summary, these early findings highlighted the importance of the FHAB domain's binding to albumin, which in turn facilitated the targeted delivery and retention of various fusion constructs within the tumor tissue, making FHAB a promising technology for the innovation of biologic therapeutics.
About
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section21E of the Securities ExchangeAct of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the timing of an IND submission, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential, 'predict,' 'project,' 'should,' 'would' and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the
Contact:
Tel: 862-754-1024
Email: jyauch@soleburystrat.com
(C) 2023 Electronic News Publishing, source